{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:40:47Z","timestamp":1792269647456,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,20]]},"DOI":"10.7759\/cureus.116594","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:57:58Z","timestamp":1789916278000},"source":"Crossref","is-referenced-by-count":1,"title":["Ocrelizumab Discontinuation After Recurrent Serious Infections in Clinically Stable Primary Progressive Multiple Sclerosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Tyler","family":"Lo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamisa","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rithvik","family":"Seri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33242","article-title":"An overview of the history, pathophysiology, and pharmacological interventions of multiple sclerosis","volume":"15","author":"Dighriri IM","year":"2023","unstructured":"Dighriri IM, Aldalbahi AA, Albeladi F, et al.. An overview of the history, pathophysiology, and pharmacological interventions of multiple sclerosis. Cureus. 2023, 15:e33242. 10.7759\/cureus.33242","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2021-0058","article-title":"Updates and advances in multiple sclerosis neurotherapeutics","volume":"13","author":"Amin M","year":"2023","unstructured":"Amin M, Hersh CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag. 2023, 13:47-70. 10.2217\/nmt-2021-0058","journal-title":"Neurodegener Dis Manag"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser SL","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, et al.. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021, 97:e1546-59. 10.1212\/WNL.0000000000012700","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251412125","article-title":"Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: the REPLACE-MS study","volume":"32","author":"Sangha KS","year":"2026","unstructured":"Sangha KS, Jakubecz C, Maynard M, et al.. Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: the REPLACE-MS study. Mult Scler. 2026, 32:338-46. 10.1177\/13524585251412125","journal-title":"Mult Scler"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00184-3","article-title":"Ageing and multiple sclerosis","volume":"22","author":"Graves JS","year":"2023","unstructured":"Graves JS, Krysko KM, Hua LH, Absinta M, Franklin RJ, Segal BM. Ageing and multiple sclerosis. Lancet Neurol. 2023, 22:66-77. 10.1016\/S1474-4422(22)00184-3","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-024-01355-w","article-title":"De-escalation and discontinuation of disease-modifying therapies in multiple sclerosis","volume":"24","author":"Gross RH","year":"2024","unstructured":"Gross RH, Corboy J. De-escalation and discontinuation of disease-modifying therapies in multiple sclerosis. Curr Neurol Neurosci Rep. 2024, 24:341-53. 10.1007\/s11910-024-01355-w","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12584-x","article-title":"MS treatment de-escalation: review and commentary","volume":"271","author":"Selmaj K","year":"2024","unstructured":"Selmaj K, Hartung HP, Mycko MP, Selmaj I, Cross AH. MS treatment de-escalation: review and commentary. J Neurol. 2024, 271:6426-38. 10.1007\/s00415-024-12584-x","journal-title":"J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00377-0","article-title":"Blood-brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies","volume":"23","author":"Zierfuss B","year":"2024","unstructured":"Zierfuss B, Larochelle C, Prat A. Blood-brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies. Lancet Neurol. 2024, 23:95-109. 10.1016\/S1474-4422(23)00377-0","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or A","year":"2021","unstructured":"Bar-Or A, Li R. Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances. Lancet Neurol. 2021, 20:470-83. 10.1016\/S1474-4422(21)00063-6","journal-title":"Lancet Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1855701","article-title":"The emerging role of B cells in immune-mediated demyelinating diseases: mechanisms and therapeutic implications","volume":"17","author":"Liu Y","year":"2026","unstructured":"Liu Y, Hasseldam H. The emerging role of B cells in immune-mediated demyelinating diseases: mechanisms and therapeutic implications. Front Immunol. 2026, 17:1855701. 10.3389\/fimmu.2026.1855701","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin FD","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, et al.. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014, 83:278-86. 10.1212\/WNL.0000000000000560","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.70039","article-title":"Primary progressive multiple sclerosis: new therapeutic approaches","volume":"45","author":"Rajabi M","year":"2025","unstructured":"Rajabi M, Shafaeibajestan S, Asadpour S, et al.. Primary progressive multiple sclerosis: new therapeutic approaches. Neuropsychopharmacol Rep. 2025, 45:e70039. 10.1002\/npr2.70039","journal-title":"Neuropsychopharmacol Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00617-3","article-title":"Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study","volume":"407","author":"Giovannoni G","year":"2026","unstructured":"Giovannoni G, Airas L, Bove R, et al.. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. Lancet. 2026, 407:2195-207. 10.1016\/S0140-6736(26)00617-3","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or A","year":"2020","unstructured":"Bar-Or A, Calkwood JC, Chognot C, et al.. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020, 95:e1999-2008. 10.1212\/WNL.0000000000010380","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears V","year":"2023","unstructured":"Mears V, Jakubecz C, Seeco C, Woodson S, Serra A, Abboud H. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD. J Neuroimmunol. 2023, 377:578066. 10.1016\/j.jneuroim.2023.578066","journal-title":"J Neuroimmunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2024.21","article-title":"Hypogammaglobulinemia and infection risk in an ocrelizumab-treated multiple sclerosis cohort","author":"Nobile S","year":"2024","unstructured":"Nobile S, Beauchemin P. Hypogammaglobulinemia and infection risk in an ocrelizumab-treated multiple sclerosis cohort. Can J Neurol Sci. 2024, 1-8. 10.1017\/cjn.2024.21","journal-title":"Can J Neurol Sci"},{"key":"ref17","unstructured":"Ocrevus (ocrelizumab) [prescribing information]. (2026). Accessed. 09\/02\/2026: https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01415-y","article-title":"Effectiveness of ocrelizumab in primary progressive multiple sclerosis: a multicenter, retrospective, real-world study (OPPORTUNITY)","volume":"20","author":"Chisari CG","year":"2023","unstructured":"Chisari CG, Bianco A, Brescia Morra V, et al.. Effectiveness of ocrelizumab in primary progressive multiple sclerosis: a multicenter, retrospective, real-world study (OPPORTUNITY). Neurotherapeutics. 2023, 20:1696-706. 10.1007\/s13311-023-01415-y","journal-title":"Neurotherapeutics"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy JR","year":"2023","unstructured":"Corboy JR, Fox RJ, Kister I, et al.. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023, 22:568-77. 10.1016\/S1474-4422(23)00154-0","journal-title":"Lancet Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.0395","article-title":"High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS","volume":"81","author":"Jouvenot G","year":"2024","unstructured":"Jouvenot G, Courbon G, Lefort M, et al.. High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS. JAMA Neurol. 2024, 81:490-8. 10.1001\/jamaneurol.2024.0395","journal-title":"JAMA Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/534818-ocrelizumab-discontinuation-after-recurrent-serious-infections-in-clinically-stable-primary-progressive-multiple-sclerosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:57:59Z","timestamp":1789916279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/534818-ocrelizumab-discontinuation-after-recurrent-serious-infections-in-clinically-stable-primary-progressive-multiple-sclerosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.116594","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,20]]}}}